Potential Drug–Drug Interactions among Hospitalized COVID-19 Patients Admitted to Medical Wards of a Referral Hospital, North-East of Iran: A Cross Sectional Study

Abstract

Background: Hospitalized corona virus disease 2019 (COVID-19) patients are special population in term of drug-drug interaction (DDI), as they receive various experimental novel medications and also most of them are elderly with various comorbidities and consequently numerous medications. The aim of present study was to assess the prevalence and determinants of potential DDIs in hospitalized COVID-19 patients admitted to the medical ward of a Referral Hospital in North-East of Iran.
 Methods: A cross-sectional study was conducted among COVID-19 inpatients between March 2020 and April 2020. Prescribed medication being taken concurrently for at least 24 h were included and checked for DDI using Lexicomp® online drug reference. Data were analyzed using SPSS19.
 Results: A total of 88 patients were evaluated. The cardiovascular disease was the most common comorbidity (30.68%). The median number of medications prescribed for each patient was 5. Hydroxychloroquine was the most common prescribed medication for COVID-19 management (92.05%). About two-third (62.5 %) of patients were exposed to at least one potential C (84.09 %) or D (52.27%) DDI and no X DDIs were found. Patients with at least five prescribed medications were at higher risk of having DDI (P = 0.001).
 Conclusion: Drug–drug interaction in COVID-19 inpatients was common. Considering these DDIs, clinical pharmacist involvement can be helpful in minimizing the risk of these potentially harmful drug combinations.

Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece

“…This is a factor that should always be considered and incorporated into risk score calculators. Previous research has demonstrated that COVID-19 patients have a high prevalence of DDIs, especially those on polypharmacy [ 57 , 62 ]. This was evident also in this study, which estimated an exponential correlation between the number of medications and the average number of DDIs.…”

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

“…The management of ADRs and DDIs from healthcare personnel, especially doctors, clinical pharmacists, and nurses who work in COVID-19 and ICU clinics, is crucial for optimal healthcare provision. Recently, it was estimated that ~40% of COVID-19 patients are exposed to at least one clinically significant DDI with antiviral drugs, with protease inhibitors as the most often associated medications in DDIs, whereas the number of patients in other works reaches up to 60% [ 94 , 134 , 149 ]. This shows that COVID-19 patients are of high risk for DDIs, as expected, and healthcare professionals should be aware of their management [ 14 ].…”